Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Sep 8;4(5):e000554.
doi: 10.1136/esmoopen-2019-000554. eCollection 2019.

B7x-from bench to bedside

Gurbakhash Kaur  1 , Murali Janakiram  1   2
Affiliations
Review

B7x-from bench to bedside

Gurbakhash Kaur et al. ESMO Open. .

Abstract

B7x is an immune checkpoint molecule which belongs to the B7 family of ligands which includes PD-L1, PD-L2, B7-H3 and HHLA2. B7x belongs to the Immunoglobulin superfamily and its protein structure is similar to other members with a N terminus peptide, IgV and IgC like extracellular domain with four cysteine residues. Its receptor is yet to be identified. B7x inhibits T cell proliferation and expansion by IL-2 dependent and non-IL-2 dependent pathways. Even though high levels of B7x mRNA can be detected in most tissues its protein expression is highly limited suggesting significant post translational control. In vivo data, show that B7x plays an important role in limiting autoimmunity in the peripheral tissues and fine-tuning autoimmune responses. B7x is highly expressed in various cancers and in prostate cancer its expression is corelated with poorer outcomes. Local production of IL-6 and IL-10 in various cancers promotes B7x expression and tumor immune evasion. B7x is especially expressed in PD-L1 negative tumors suggesting that this may be an important method of immune evasion in these tumors. Currently drug development, targeting B7x through various mechanisms including monoclonal antibodies and antibody drug conjugates are in development in cancers and increasing B7x expression with fusion proteins in autoimmune diseases is underway.

Keywords: B7 homolog 4; B7-H4; B7S1; B7x; VTCN1; immune checkpoint blockade; immunotherapy; novel immune checkpoints.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Zang X, Loke P'ng, Kim J, et al. . B7x: a widely expressed B7 family member that inhibits T cell activation. Proc Natl Acad Sci U S A 2003;100:10388–92. 10.1073/pnas.1434299100 - DOI - PMC - PubMed
    1. Choi I-H, Zhu G, Sica GL, et al. . Genomic organization and expression analysis of B7-H4, an immune inhibitory molecule of the B7 family. J Immunol 2003;171:4650–4. 10.4049/jimmunol.171.9.4650 - DOI - PubMed
    1. Sica GL, Choi IH, Zhu G, et al. . B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity 2003;18:849–61. 10.1016/S1074-7613(03)00152-3 - DOI - PubMed
    1. Prasad DVR, Richards S, Mai XM, et al. . B7S1, a novel B7 family member that negatively regulates T cell activation. Immunity 2003;18:863–73. 10.1016/S1074-7613(03)00147-X - DOI - PubMed
    1. Jeon H, Vigdorovich V, Garrett-Thomson SC, et al. . Structure and cancer immunotherapy of the B7 family member B7x. Cell Rep 2014;9:1089–98. 10.1016/j.celrep.2014.09.053 - DOI - PMC - PubMed